MSC Millennium Silver Corp

Meridex Software Corp. ("Meridex") (TSX VENTURE:MSC.H) is pleased to announce
that it has entered into a binding Share Purchase Agreement to acquire Biogen
Sciences Inc. ("BSI"), a privately held B.C. biopharmaceutical company focused
on drug discovery and development of the therapeutic science of cannabinoids. 


Under the terms of the agreement Meridex will purchase 100% of the outstanding
equity of BSI by issuing 4,000,000 million shares and, upon completion of the
transaction, Biogen will become a wholly owned subsidiary of Meridex. 


"This is a compelling strategic opportunity for Meridex," said Craig Schneider,
President & CEO. "By acquiring BSI we are positioning our company to capitalize
not only on the surge of investor interest in the medical marihuana space but
also the continuing strong growth in the life-science sector. With nearly $3
billion dollars being raised for Canadian companies in 2013 within the life
science sector we are confident being a part of this space will allow us to
accelerate our shareholder growth and create value. 


"To reflect the company's new direction and reflect our new business strategy we
have changed our name to 'Cannabis Technologies Inc.'." Additional information
can be found on the company at www.cannabis-tech.com.


ABOUT BSI

BSI is a private biopharmaceutical drug discovery and development company
uniquely focused on the therapeutic potential of cannabinoids. The company
consists of two divisions:


Drug Discovery & Development - BSI is utilizing its proprietary "Cannabinoid
Drug Design Platform" to identify new bioactive compounds within the marijuana
plant that interact with certain gene responsible for specific diseases. BSI's
extensive research and intellectual properties will initially be focused on the
development of several new cannabinoid based treatments for glaucoma, cancer &
angiogenesis, Inflammation and pain. 


Cultivation & Breeding - BSI's botanical research division has begun the
research & development into the individual strains and clones that will produce
the raw material bases for future pharmaceutical research. To comply with the
demands of the Pharmaceutical industry, a phytopharmaceutical feedstock must
meet high expectations regarding the minimum and maximum content of a range of
compounds. Cultivation techniques and pharmaceutical levels of exacting chemical
consistency are critical for all applications to regulatory authorities. 


ON BEHALF OF THE BOARD

Craig Schneider, President and CEO

Forward-Looking Statements

This news release may contain forward-looking statements and information based
on current expectations. These statements should not be read as guarantees of
future performance or results. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements.
Although such statements are based on management's reasonable assumptions, there
can be no assurance that such assumptions will prove to be correct. We assume no
responsibility to update or revise them to reflect new events or circumstances.


Additionally, there are known and unknown risk factors which could cause Meridex
Software's actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking information contained herein. 


All forward-looking information herein is qualified in its entirety by this
cautionary statement, and Meridex Software disclaims any obligation to revise or
update any such forward-looking information or to publicly announce the result
of any revisions to any of the forward-looking information contained herein to
reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that
clinical trials will not be successful, or be completed, or confirm earlier
clinical trial results, risks associated with obtaining funding from third
parties, risks related to the timing and costs of clinical trials and the
receipt of regulatory approvals


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of the release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Meridex Software Corp.
Craig Schneider
President and CEO
604.669.7207
604.683.2506 (FAX)
www.cannabis-tech.com

Millennium Silver (TSXV:MSC)
Historical Stock Chart
From Mar 2024 to Apr 2024

Millennium Silver (TSXV:MSC)
Historical Stock Chart
From Apr 2023 to Apr 2024